# Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

> **NCT05603143** · PHASE3 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 468 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Obeldesivir
- **DRUG:** Obeldesivir Placebo

## Key facts

- **NCT ID:** NCT05603143
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-05
- **Primary completion:** 2023-11-07
- **Final completion:** 2023-11-07
- **Target enrollment:** 468 (ACTUAL)
- **Why stopped:** The study was stopped early as it was determined there would not be a statistically significant treatment effect associated with the primary endpoint due to the low number of events.
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05603143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05603143, "Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05603143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*